Name: 𝘒𝘙𝘈𝘚 in Focus: Navigating the Mutation-Driven Oncology Landscape – Nursing
Availability: InStock

Activity Overview

Over the past decade, oncology has begun to leverage a rapidly maturing effort to target the KRAS protein in KRAS-altered cancers. This has led to the introduction of targeted therapies with the potential to offer unprecedented benefit to patients. Still, these agents differ greatly in their mechanisms of action, relevant alterations, and adverse event profiles.

In this activity, expert faculty discuss the state of the art for targeting the RAS/MAPK signaling pathway in solid malignancies, with different modules focusing on the current efforts in gastrointestinal, lung, and gynecologic cancers.

Target Audience

Burst #1

This activity is directed toward medical oncologists, molecular pathologists, and other oncology health care professionals

Burst #2

This activity is directed towards medical oncologists, pulmonologists, thoracic surgeons, radiation oncologists, and other health care professionals

Burst #3

This activity is directed towards medical oncologists, gastroenterologists, surgical oncologists, radiation oncologists, and other health care professionals

Burst #4

This activity is directed towards medical oncologists, gynecologic oncologists, radiation oncologists, pathologists, and other health care professionals

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Burst #1

Explain the role of KRAS/RAS mutations in solid tumors

Burst #2 & #3

Evaluate efficacy and safety of current and emerging KRAS/RAS-targeted therapies in solid tumors
Incorporate clinical trial data on KRAS/RAS-targeted therapies into treatment selection considerations for individual patients with solid tumors

Burst #4

Evaluate efficacy and safety of current and emerging KRAS/RAS-targeted therapies in solid tumors
Apply appropriate AE mitigation and management strategies for patients with solid tumors receiving KRAS/RAS-targeted therapies

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

PER^® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.

This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.

The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.

𝘒𝘙𝘈𝘚 in Focus: Navigating the Mutation-Driven Oncology Landscape – Nursing

David S. Hong MD

Kathryn C. Arbour, MD

Shubham Pant, MD, MBBS

Alison Schram, MD

GET STARTED WITH THIS PROGRAM:

You Also Might Like...